{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["57(1)"],"submitter":["Quan L"],"pubmed_abstract":["<h4>Objective</h4>Smoldering multiple myeloma (SMM) is a slowly progressive, asymptomatic plasma cell disorder. This meta-analysis evaluated the efficacy and safety of novel agent-based therapies for SMM, particularly high-risk patients.<h4>Methods</h4>PubMed, Embase, Web of Science, Ovid MEDLINE, Scopus and ClinicalTrials.gov were searched for randomized controlled trials (RCTs) and non-randomized studies from 2003 to 2024.<h4>Results</h4>Nineteen studies were included, comprising 5 RCTs and 14 non-randomized, single-arm trials. These studies involved a total of 1217 patients. Pooled analysis of intervention groups showed progression-free survival (PFS) and overall survival (OS) rate at 12 months of 94% (95% CI, 89%-98%) and 99% (95% CI, 97%-100%), respectively. The overall response rate "],"journal":["Annals of medicine"],"pagination":["2560679"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12466189"],"repository":["biostudies-literature"],"pubmed_title":["Efficacy and toxicity of treatment of smoldering multiple myeloma: a systematic review and meta-analysis."],"pmcid":["PMC12466189"],"pubmed_authors":["Ma C","Cao X","Sun C","Quan L","Li Q"],"additional_accession":[]},"is_claimable":false,"name":"Efficacy and toxicity of treatment of smoldering multiple myeloma: a systematic review and meta-analysis.","description":"<h4>Objective</h4>Smoldering multiple myeloma (SMM) is a slowly progressive, asymptomatic plasma cell disorder. This meta-analysis evaluated the efficacy and safety of novel agent-based therapies for SMM, particularly high-risk patients.<h4>Methods</h4>PubMed, Embase, Web of Science, Ovid MEDLINE, Scopus and ClinicalTrials.gov were searched for randomized controlled trials (RCTs) and non-randomized studies from 2003 to 2024.<h4>Results</h4>Nineteen studies were included, comprising 5 RCTs and 14 non-randomized, single-arm trials. These studies involved a total of 1217 patients. Pooled analysis of intervention groups showed progression-free survival (PFS) and overall survival (OS) rate at 12 months of 94% (95% CI, 89%-98%) and 99% (95% CI, 97%-100%), respectively. The overall response rate ","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Dec","modification":"2026-05-01T03:16:04.37Z","creation":"2026-05-01T03:10:16.666Z"},"accession":"S-EPMC12466189","cross_references":{"pubmed":["40994100"],"doi":["10.1080/07853890.2025.2560679"]}}